Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04176471
Other study ID # 53274
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 1, 2020
Est. completion date January 31, 2025

Study information

Verified date March 2020
Source Stanford University
Contact Sonia L Bonifacio, MD
Phone 650-723-5711
Email soniab1@stanford.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The TIME study is a randomized, controlled trial to evaluate impact on early measures of neurodevelopment and the safety profile of therapeutic hypothermia in term neonates with Mild Hypoxic-Ischemic Encephalopathy who are < 6 hours of age. Neurodevelopmental outcome will be assessed at 12-14 months of age. The study will enroll 68 neonates randomized to therapeutic hypothermia or normothermia across 5 centers in California.


Description:

The TIME study is a multi-center randomized, controlled trial of Therapeutic Hypothermia (TH) (33.5°C ± 0.5° for 72 hours) versus normothermia using targeted temperature management, initiated within 6 hours after birth in term neonates with Mild Hypoxic-Ischemic Encephalopathy (HIE). Mild encephalopathy will be identified using the 6 component modified Sarnat exam as in the Neonatal Research Network of the National Institute of Child Health and Human Development trials of TH for moderate-severe encephalopathy and will be expanded to include features of mild encephalopathy. Eligible subjects must demonstrate ≥ 2 exam abnormalities (mild, moderate, severe) but without evidence of moderate-severe encephalopathy (≥ 3 moderate or severe features). The primary outcome is neurodevelopmental outcome at 12-14 months of age. Secondary outcomes include evaluating the safety profile of therapeutic hypothermia in patients with Mild HIE. Therapeutic hypothermia is well tolerated and did not demonstrate serious safety concerns when evaluated in multiple large studies of neonates with moderate-severe HIE. It is now being applied by some practitioners to neonates with Mild HIE without systematic evidence of benefit or potential harm. This data will be necessary in order to develop and larger trial of efficacy to be determined at 2 years of age.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 68
Est. completion date January 31, 2025
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 6 Hours
Eligibility Inclusion Criteria (must meet all 3):

1. Neonates born at = 36 0/7 weeks

2. Neonatal signs or contributing factors consistent with an acute peri-partum or intra-partum event (must meet a or b):

1. pH = 7.0 or Base deficit = 16 in any umbilical cord or baby specimen at = 1 hr of age OR

2. No umbilical cord or baby blood gas at = 1 hr of age OR pH 7.01-7.15 or Base deficit 10-15.9 in any cord or baby specimen at = 1 hr of age AND at least one of the following

- Apgar score at 10 min = 5

- Continued need for resuscitation at 10 min (chest compressions, bag mask ventilation, intubation with positive pressure ventilation)

- Acute Perinatal Event: uterine rupture, placental abruption, cord accident (prolapse, rupture, knot or tight nuchal cord), maternal trauma, maternal hemorrhage or cardiorespiratory arrest, fetal exsanguination from either vasa previa or feto-maternal hemorrhage

- Fetal heart rate monitor pattern consistent with acute peripartum or intrapartum event (category III trace: no heart rate variability, presence of recurrent late or variable decelerations, bradycardia, or sinusoidal pattern)

3. Evidence of Mild Encephalopathy on Modified Sarnat Exam.

- Presence of at least 2 signs of mild, moderate or severe encephalopathy with no more than 2 moderate or severe findings in the 6 tested categories (level of consciousness, spontaneous activity, posture, tone, neonatal reflexes (suck and moro), and autonomic nervous system

Exclusion Criteria:

- Patients < 36 0/7 weeks birthweight < 1800gm; congenital or chromosomal anomaly associated with abnormal neurodevelopment or death; patients with moderate or severe HIE (by Sarnat exam or presence of clinical or electrographic seizures) identified within 6 hours after birth; core body temperature < 34°C for more than 1 hour prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Therapeutic Hypothermia
Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
Normothermia
Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.

Locations

Country Name City State
United States Loma Linda Children's Hospital Loma Linda California
United States Benioff Children's Hospital Oakland Oakland California
United States Children's Hospital Orange County Orange California
United States Stanford University Palo Alto California
United States Rady Children's Hospital San Diego California

Sponsors (2)

Lead Sponsor Collaborator
Stanford University Thrasher Research Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Age at Randomization Age in hours and minutes after birth at randomization First 24 hours of life
Other Age at Initiation of Treatment Age in hours and minutes after birth at which normothermia or therapeutic hypothermia are initiated First 24 hours of life
Other Percentage of participants with disability at 2 years of age Most enrolled neonates will be followed in high-risk infant follow-up clinics. We will track developmental outcome at 2 years of age for all enrolled patients and determine the proportion of treated and control patients who abnormal measures of neurodevelopment 2 years
Primary Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) will be assessed at 12-14 months of age. The mean score for a 12 month old normally developing infant is 109 with a standard deviation of 16.5. Higher scores are associated with normal development. Assessment takes up to 15 minutes and will be conducted at 12-14 months of age
Primary Alberta Infant Motors Scale (AIMS) Alberta Infant Motors Scale (AIMS) will be assessed at 12-14 months of age. The AIMS score is determined by assessment of 4 positions and scoring the least and most mature position identified. The score is converted to a percentile for age with those in the 5th to 25th percentile identified as suspicious motor development and those with a score corresponding to < 5th percentile being identified as abnormal motor development. Assessment takes up to 15 minutes and will be conducted at 12-14 months of age
Secondary Percentage of participants with sinus bradycardia Investigators will determine the proportion of treated and control subjects who develop sinus bradycardia (HR < 80) during the intervention period (72 hours). 72 hours
Secondary Percentage of participants thrombocytopenia Investigators will determine the proportion of treated and control subjects who develop thrombocytopenia (platelet count of < 150 x 109/L) during the intervention period 72 hours
Secondary Percentage of patients who require intubation and mechanical ventilation Investigators will determine the proportion of treated and control subjects who require intubation and mechanical ventilation 72 hours
Secondary Percentage of patients with need for central line Investigators will determine the proportion of treated and control subjects who have a central line (umbilical or PICC) 72 hours
Secondary Percentage of participants with Persistent Pulmonary Hypertension (PPHN) Investigators will determine the proportion of treated and control subjects who have a clinical diagnosis of PPHN or who receive inhaled nitric oxide 72 hours
Secondary Percentage of participants exposed to sedating or analgesic medications Investigators will determine the proportion of treated and control subjects who receive narcotics or benzodiazepines 72 hours
Secondary Percentage of participants exposed to inotropic agents Investigators will determine the proportion of treated and control subjects who receive inotropic support 76 hours
Secondary Percentage of participants diagnosed with seizures Investigators will determine the proportion of treated and control subjects who develop clinical and or electrographic seizures During initial hospital stay up to 30 days
Secondary Age at initiation of feeds Investigators will determine the age at which enteral feeds are initiated in treated and control patients During initial hospital stay up to 30 days from date of admission
Secondary Age at full enteral feeds Investigators will determine the age at which full enteral feeds or breastfeeding ad lib is achieved in treated and control patients During initial hospital stay and up to 30 days from date of admission
Secondary Percentage of participants who require feeding assistance at discharge Investigators will determine the proportion of treated and control patients who require feeding support at discharge (NG tube or G-Tube feeds) At time of discharge from hospital, up to 30 days from admission
Secondary Percentage of participants with fat necrosis and hypercalcemia Investigators will determine the proportion of treated and control patients who have a diagnosis of fat necrosis and hypercalcemia From study entry to day of hospital discharge, up to 30 days from admission
Secondary Percentage of participants discharged on anti-convulsant medications Investigators will determine the proportion of treated and control patients who are discharged home on anti-convulsant medications At time of discharge from hospital, up to 30 days from admission
Secondary Count of participants with brain injury on MRI Investigators will determine the number of treated and control patients who have brain injury on MRI At time of discharge from hospital, up to 30 days from admission
Secondary Length of Hospital Stay Investigators will determine the length of hospital stay for treated and control patients At time of discharge from hospital, up to 30 days from admission
Secondary Percentage of participants breastfeeding at discharge Investigators will determine the proportion of treated and control patients who are breastfeeding at discharge At time of discharge from hospital, up to 30 days from admission
Secondary Percentage of participants with death and/or hospice at discharge Investigators will determine the proportion of treated and control patients who die or are discharged home on hospice At time of discharge from hospital, up to 30 days from admission
See also
  Status Clinical Trial Phase
Completed NCT05471336 - Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE) N/A
Recruiting NCT05514340 - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy Phase 2
Recruiting NCT04603547 - Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy
Completed NCT01913340 - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Phase 1/Phase 2
Completed NCT00581581 - CoolCap Followup Study-Coordination of Participating Centers N/A
Recruiting NCT05772416 - Neonatal Neurological Examination to Detect Infants at Risk
Completed NCT03122808 - Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study
Recruiting NCT02544100 - Neonatal Neurologic Intensive Care Network of China
Completed NCT03380013 - OMT to Improve Feeding After Hypothermia N/A
Active, not recruiting NCT03409770 - Optimising the Duration of Cooling in Mild Encephalopathy N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Not yet recruiting NCT06098833 - Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia Phase 2
Not yet recruiting NCT05756296 - The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era
Recruiting NCT04432662 - Darbepoetin in Neonatal Encephalopathy Trial Phase 2
Recruiting NCT02793999 - Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
Not yet recruiting NCT05889507 - Cooling in Mild Encephalopathy N/A
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Completed NCT01309711 - Magnetic Resonance Biomarkers in Neonatal Encephalopathy
Recruiting NCT04225975 - Neonate Cerebral Activity in Immediate Post Partum N/A
Recruiting NCT05610085 - A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures Phase 2